Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes
Authors' conclusion
After medication-date validation, a higher count was more common than a lower count, though it occurred in fewer than half of patients.
Study context
- Population
- Adults with T2D (ICD-10 E11 without E10) initiating semaglutide, liraglutide, dulaglutide or tirzepatide, with ≥1 recorded baseline non-GLP-1 glucose-lowering active substance; median age 60 years, 53.9% women
- Participants
- 3,660 adults
- Outcome
- Change in recorded background glucose-lowering active-substance counts after GLP-1 RA or dual GIP/GLP-1 RA initiation (lower count, no change, higher count)
Methodological detailsanonymized electronic health records, Polish private outpatient network
- Anonymized electronic health records
- Polish private outpatient network
Main finding
As reported in the abstract
Recorded background glucose-lowering active-substance count
- Median within-patient change (IQR 0-1)
- 0
- Lower count
- 17.2%
- No change
- 38.8%
- Higher count
- 44.0%
- Higher count, dulaglutide (most frequent)
- 52.9%
- Higher count, tirzepatide (least frequent)
- 20.4%
Observational data: associations, not effects.
Original publication
Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes Res Clin Pract. Published 10 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →